Pharming Group N.V. PHAR · Stock Open Pharming Group N.V. in new tab
Analyst price targets
Recent rating changes, newest first
Pharming Group N.V. Analysis (PHAR)
Is Pharming Group N.V. a good investment? Pharming Group N.V. (PHAR) is currently trading at 12.46 USD. Market analysts have a consensus price target of 35.10 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 39.78. This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule: Pharming Group N.V. is expected to release its next earnings report on Nov. 5, 2026. The market consensus estimate for Forward EPS is 0.18.
Investor FAQ
Does Pharming Group N.V. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Pharming Group N.V.?
Pharming Group N.V. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 5, 2026. The company currently has a trailing EPS of 0.32.
Company Profile
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kd inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3Kd inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Community Discussion